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INTRODUCTION: 
Humans have seen the emergence of many new diseases throughout the 
history. In the 20
th
 century the disease which came to the fore and made the 
human race panic the most was Acquired Immune deficiency Syndrome 
(AIDS), which is caused by Human Immunodeficiency Virus (HIV). The 
disease surfaced in the 1980s, and three decades later, our combat with the 
disease is still on. Hence AIDS/HIV remains one of the most dreaded 
public health challenges. 
Although the overall rate of new infections appears to decline, epidemics 
among key populations continue to grow alarmingly. This includes 
injection drug users (IDU), homosexuals and sex workers. Remarkable 
progress has been made in such populations over the last decade-yet 
significant challenges remain. 
The absence of a cure or preventive vaccine to the disease has had its 
negative effect on economy and development of various developing 
countries like India. But a positive response from the government, NGOs 
and WHO have effectively brought down the transmission rates among the 
most vulnerable populations in India. Many studies contribute to the 
evidence base for emphasis on prevention as the most cost beneficial and 
effective national response. 
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EPIDEMIOLOGY OF HIV IN INDIA: 
HIV Sentinel Surveillance 
[1]
 (HSS) formalised by the National AIDS 
Control Organisation (NACO) in India is the best source of epidemiology 
of HIV/AIDS in India. According to HSS 2012-2013, the overall 
prevalence of HIV in India continues to be as low as 0.35%. Nagaland, 
Mizoram, Arunachal Pradesh, Andhra Pradesh, Karnataka, Chhattisgarh, 
Gujarat, Maharashtra, Delhi and Punjab are the states in which the HIV 
prevalence was more than the national average. Bihar, Rajasthan and 
Odisha recorded prevalence less than the national average. The prevalence 
of HIV in Tamil Nadu is 0.36% which is close to the national average. 
Although all the states in India showed a prevalence of less than one 
percentage, there are certain areas within the states including Tamil Nadu 
which showed prevalence rate more than 1%. The estimated number of 
people who live with HIV in India has declined from 23.2lakhs in 2006 to 
20.9lakhs in 2011. 
In Tamil Nadu the prevalence rate 
[2]
 is highest among the transgender 
group (3.82%), Female sex workers (FSW) (2.69%) and men having sex 
with men (MSM) (2.4%) according to official data. 
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Another alarming part of HIV in India is the prevalence of Tuberculosis 
and HIV co-infection. A study done on the prevalence of tuberculosis in 
HIV positive patients attending ART centre in Maharashtra showed that 
about 17% of the HIV positive patients had tuberculosis co-infection. 
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AIM OF THE STUDY 
To document, 
1) The clinical profile 
2) The laboratory profile 
3) Clinical staging 
4) Immunological staging 
in 100 randomly selected newly diagnosed HIV infected patients attending  
ART centre , Tirunelveli medical college hospital,  Tirunelveli from June 
2014 to May 2015. 
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  REVIEW OF LITERATURE 
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HUMAN IMMUNO DEFICIENCY VIRUS: 
Human immunodeficiency viruses 
[3]
 belong to the family retroviridae and 
subfamily lentiviridae. Two types of human viruses are recognised in this 
subfamily HIV-1 and HIV-2. Both types of virus differ in geographical 
distribution, molecular and biological characteristics as well as in the 
manner of their transmissibility. 
There are 3 types of HIV-1, which includes, 
1) HIV-1 major group(HIV-1M) 
2) HIV-1 new (HIV-1N) 
3) And HIV-1 outlier(HIV-1O) 
The most common cause of HIV disease all over the world and India is 
HIV-1. HIV-2 was identified in West Africa. It was earlier believed to be 
confined only to West Africa. But a number of cases which can generally 
be traced to West Africa or to sexual contacts with West African 
populations have been identified throughout the world including India. 
HIV-1 M group is the cause of pandemic all over the world. The human T 
lymphotropic viruses, HTLV-1 and HTLV-2 are other types of retroviruses 
that can cause diseases in humans. 
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MORPHOLOGY OF HIV 
[3]
 
HIV is an enveloped, positive stranded, ribonucleic acid virus. The HIV 
virion has an icosohedral structure containing numerous external spikes or 
knobs. The spikes or knobs are made of glycoproteins gp120 and gp41 in 
HIV-1 and gp-36 in HIV-2. The HIV virion measures 120nm in diameter. 
The spikes or knobs are uniformly arranged over a lipid bilayer. The two 
positive stranded RNA molecules are embedded in a protein capsid (p24) 
together with the so called viral enzymes (viral RNA dependent DNA 
polymerase (pol), also called as the reverse transcriptase enzyme ) and 
nucleocapsid proteins p9 and p7. The capsid is surrounded by a matrix 
layer which in turn is enclosed by a lipid bilayer, called the envelope. 
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TRANSMISSION OF HIV 
[4]
 
         Transmission of HIV is commonly through sexual contact which 
includes both heterosexual and male to male sexual contact. 
          It can also be transmitted through blood and blood products, and in 
injection drug users (IDU) through the syringes they share. 
          The other mode of transmission is the so called vertical transmission, 
which is from mother to infant, which may occur during intrapartum 
period, perinatal period or via breast milk. 
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SEXUAL TRANSMISSION: 
          It is the commonest mode of transmission of HIV. In the developing 
countries like India, heterosexual transmission is the primary mode of 
transmission. In western countries there is a re-emergence of male to male 
sexual transmission. 
          The presence of other sexually transmitted diseases like Treponema 
pallidum, Haemophilus ducreyi or Herpes simplex virus infection leads to 
genital ulceration and hence eases the transmission of HIV.  
 INJECTION DRUG USERS (IDU): 
           Injection drug users are exposed to HIV while sharing injection 
equipments such as needles and syringes, water in which they mix the 
drugs or the cotton which is used for filtering the drugs.  
         Apart from transmission during intravenous injection , subcutaneous 
and intramuscular injection can also transmit HIV in them. 
BLOOD AND BLOOD PRODUCTS: 
        HIV can be transmitted to persons who receive blood transfusions or 
blood products from HIV infected donors. There is also evidence to 
support that HIV spreads through transplanted tissue. However the vast 
majority of HIV through this route was before 1985, after that, the 
transmission through blood products is on the decline due to initiation of 
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mandatory tests for HIV in donated blood. Eventhough testing for HIV in 
donated blood has become universal even in developing countries, in some 
countries with poor resources; HIV continues to be transmitted through 
blood and blood products.  
        Earlier , only screening for HIV – 1 in donated blood was followed, 
but now developed countries are also beginning to screen for HIV – 2, 
since HIV – 2 infection is also occurring sporadically in all parts of the 
world. 
MOTHER TO CHILD TRANSMISSION:  
       HIV can be transmitted from HIV infected mother to fetus during 
intrapartum period, during birth or by breast feeding. The probability of 
HIV transmission from pregnancy till the perinatal period is about 15% to 
25% in developed countries and 25% to 35% in developing countries. This 
difference is due to inadequate prenatal care in developing countries. 
     Breast feeding is an important mode of transmission in developing 
countries, where the mother tends to breast feed the baby for prolonged 
periods. 
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OCCUPATIONAL TRANSMISSION: 
         This occurs in the health care setting, mainly in the health care 
workers and laboratory workers. Analysis of many studies has indicated 
that the transmission of HIV from infected person to health care workers 
through needle stick injury has 0.3% chance of transmission and mucous 
membrane exposure has 0.09% chance of transmission, if the exposed 
person is not treated with anti retroviral drugs within 24 hours from the 
exposure time. The emergence of post exposure prophylaxis has however 
reduced this occupational hazard in health care workers. 
HIV TRANSMISSION BY OTHER BODY FLUIDS: 
          Saliva of a HIV infected person contain HIV, but the transmission is 
negligible because, the saliva contains endogenous antiviral substances. In 
addition there are also glycoproteins like mucin and thrombospondin I, 
which prevent the transmission of HIV through saliva. Though other body 
fluids like tears, sweat and urine also contain HIV, there is no evidence of 
transmission through these body fluids. However ,for  health care workers , 
it is important to follow universal preventive measures even when they are 
dealing with the above said body fluids from HIV infected individuals. 
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PATHOGENESIS 
[4]
 
‘CD4’ molecules on cells and ‘gp120’ molecules on HIV have affinity for 
each other. A chance contact leads to firm bondage and lays the foundation 
for cell invasion. T-helper lymphocytes (including immature, mature and 
derived cells), monocytes, macrophages, dendritic cells (DCs) [in 
epidermis (Langerhans cells), mucosal surfaces of alimentary and genital 
tracts, lymphoid depots and tissues], epithelial cells lining mucosae of the 
said tracts and microglial cells of the central nervous system (CNS) carry 
CD4 molecules. HIV targets them for replication. 
Just establishment of ‘gp120↔CD4’ bond does not ensure successful cell 
invasion, gp120 must also bind with one or more cytokines on the surfaces 
of target cells, which act as co-receptors. Two co-receptors, essential for 
HIV, are CCR5 and CXCR4. Due to minute differences in gp120 
molecules, strains of HIV differ in their affinity to them. Other co-
receptors (CCR2b, CCR3, STRL33 and GPR15) have also been identified. 
After binding with CD4, the configuration of gp120 is changed. New sites 
are opened on it for binding with co-receptors. After 
“CD4↔gp120↔CCR5/CXC4” binding, gp41 also undergoes changes. It 
emerges on the surface, by the side of gp120. Now, gp41 can establish 
contact with the target cell membrane. Molecules of ‘fusion’ peptides (FPs) 
are inserted on the exposed ends of gp41. FPs cause fusion of viral 
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envelope with the cell membrane. An opening is thus created. Viral 
genome then enters the target. This opening is sealed after viral entry. Only 
one virus can infect a cell. The infected cell cannot get rid of HIV. 
In an immunologically normal adult, immune response, as in other 
infections, would be expected in HIV infection too. Immune control of any 
viral replication is achieved through virus specific CD4+ T-cells, antibody 
dependent cellular toxicity and by CTLs 
[5]
. But, in HIV infection CD4+ T-
cells, themselves, are the viral targets. Due to the vagaries of HIV antigens, 
the magnitude and pattern of antibody response can be unreliable. 
Antibody levels may be high, but viral neutralisation, not proportionately 
so. Moreover, mutant strains can escape immune damage. CTLs are the 
body’s major effective measure of inhibiting HIV replication. Efficiency of 
their action determines the future course of events. Initially, in HIV 
infection, they are variably successful but later on they fail. As infection 
continues, CTL counts fall, due to AAD(Accelerated Apoptotic Death). On 
exhaustion of CD8+ cells, CTL response gets suppressed (immuno 
suppression). Other reasons for lack of effective immune control of viral 
replications are magnitude of HIV reservoirs in body, functional defects in 
immunocompetent cells, lifestyle (intravenous drug abuse) of patient and 
his genetic make-up. Balance of forces ‘producing and killing HIV’ sets a 
level of viral load in body. Higher the ‘set point’, worse is the prognosis. 
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When CTL response declines, the ‘set point’ gets raised and the disease 
progresses faster. 
 
PICTURE DEPICTING THE PATHOGENESIS OF HIV/AIDS 
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       From the moment of primary infection to the development of advanced 
stage of the disease, there is a combination of both immunological and 
pathogenic events which are more complex and variable in each individual. 
It is also worth noting that the pathogenic mechanisms of the disease 
caused by HIV, involves multiple factors and is also multiphasic, hence 
differing at different stages of the disease 
[6]
. 
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CD4+ T Lymphocytes 
[7] 
Infected cells suffer most and by various mechanisms. Even non infected 
cells suffer ‘accelerated apoptotic death’ (AAD), induced by excess, 
prolonged activation. Molecular basis of AAD is not clear. Non-infected 
cells, carrying viral antigens on the surface, are sequestered by anti-viral 
IgM/IgG antibodies and killed by cytotoxic lymphocyte (CTL) T-cells. 
Cells with lesser viral loads may not die but they get functionally impaired. 
Deficient antigen induced proliferation and cell-mediated immune (CMI) 
response are the major defects In active phase of infection, CD4+ loss can 
be up to 2 million cells per day. 
GRAPH DEPICTING THE RELATION BETWEEN VIRAL LOAD 
AND CD4 COUNT 
[8]
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 Sometimes, loss of non-infected cells can be more than that of infected 
cells. In the initial phases of infection, enormous loss does not reflect as an 
immediate, proportionate drop in their blood count, due to compensatory 
proliferation of precursor cells. CD4+ counts start dropping, when the virus 
kills lymphoid precursor cells and replenishment of lost cells becomes 
increasingly inadequate 
[9]
.  
PATHOGENESIS OF IMMUNODEFICIENCY 
Incubation period 
After transmucosal (and also parenteral) transmission, HIV reaches and 
establishes in T-cell areas of lymph nodes. Mucosal and nodal changes and 
early viral replication are clinically silent. Viral release into circulation 
increases slowly. Viral antigens appear in blood. HIV infection clinically 
manifests in 3 to 6 weeks post-exposure in up to 90% cases. 
Acute retroviral syndrome (ARVS) 
Increasing viraemia makes the infection manifest as ‘flu like’ episode, 
called ARVS (sore throat, myalgia, fever, rash, fatigue, enlarged nodes, 
diarrhoea and vomiting). Proportionate to the viral load in blood, there is a 
downward spike in CD4 count. With virus dissemination to all lymph 
depots, the infection becomes multi-systemic and permanent. Due to the 
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host’s immune response, viral replication is restrained. Symptoms abate in 
2 to 4 weeks. CD4 count gets corrected. Patient is sero-converted. He may 
be diagnosable, also by virus/its components in blood. After recovery, the 
patient goes through a variable period of clinical latency. Two types of 
‘latent’ phases are possible. 
 
Virus non-productive latent (VNPL) phase 
                              Persons with a strong immune response take care of 
total viral replication while the virus lurks in reservoirs, in peaceful 
coexistence, awaiting an opportunity to reactivate. This can continue for 
months to years. The patient is sero-positive, has no viral load in blood and 
has a normal immune profile. Cases in VNPL phase are clinically healthy 
and symptom-free. They may even be noninfective to sex partners but are 
not safe blood donors. 
 
Virus low-productive subdued (VLPS) phase 
                     If the initial immune response is not strong enough to restrain 
viral replication completely, virus is produced in minute amount, but not 
sufficient to produce continuous clinical manifestations. The virus keeps on 
infecting new CD4+ T-cells. Its replication steadily increases without 
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causing a drop in their count. A period of apparent inaction continues over 
a variable period, depending upon the magnitude of viral replication. 
Patient is sero-positive. His viral load depends on the ‘set point’. CD4 
count, usually normal, shows a trend of gradual annual decline (25 to 60 
cells per year). Cases in VLPS phase are not totally symptom-free. They 
may have mild/moderate episodes of symptoms due to GIT lesions. In 
between the episodes, they do not appear seriously ill. There may be ‘non-
alarming’ weight loss. Their infectivity is proportional to viral load. 
 
Persistent generalised lymph adenopathy (PGLA) 
Some cases in VLPS phase have PGLA. Enlarged nodes show nonspecific 
polyclonal hyperplasia of ‘B’ and ‘T’ cell areas. Abnormal antibodies and 
their effects may appear. Some cases may have few, mild symptoms (fever, 
rash, fatigue). Constitutional symptoms indicate that the next stage is 
imminent very soon. 
 
Stage of Immunodeficiency (SIMD) 
[10]
 
Viral replication continued over a long period, plays havoc with the 
immune apparatus. CD4+ T-cell plays the role of an orchestra conductor’ 
for humoral immunity as well as CMI. Dysfunction of humoral immunity 
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is indirect due to influences on B-cells. Dysfunction of CMI is the direct 
result of loss of T lymphocytes. Progressive, relentless loss and 
dysfunction of almost all subsets of immunocompetent T-cells are the 
major events. Lymph nodes, thymus, bone marrow, lymphoid depots in 
tissues and gastrointestinal tract get depleted of T-cells. They show 
structural disorganisation and atrophy. CD4 and CD8 cell counts in blood 
drop. SIMD invites opportunistic pathogens and activates the pre-existing 
latent ones. CD4 count in peripheral blood is used as an indicator of 
immune function. It is however not a perfect guide. 2% of the total pool of 
CD4 cells is in blood and the rest is in tissues. Even a minute change in the 
distribution can bring about a vast change in the count. In some studies, 
CD4 percentage was a better marker than CD4 count. As of today, CD4 
count is used and has served as a useful practical guide. Time required for 
progress from infection to SIMD is variable. It depends on the summation 
of dynamics of viral replication and the host’s anti-HIV immune response. 
It can be prolonged by ART regime. Usually, the period cannot be 
predicted with certainty, except in cases in VLPS, showing decline of CD4 
count at a steady rate. SIMD is reached in 2 to 5 years in ‘rapid 
progressors’. ‘Slow progressors’ take more than 10 years. 8 to10 years is 
the period required for majority of the cases. Hallmarks of SIMD are 
increasing viral load, increasing titer of viral components in blood and CD4 
count below 300/mL. An ill-understood group consists of patients in whom 
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CD4 counts are below 300/mL and yet who show no manifestations of 
immunodeficiency. Co-existing STD/TB viral infections accelerate the 
onset of SIMD. SIMD aggravates these diseases. A vicious cycle is thus 
established 
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ACQUIRED IMMUNO DEFICIENCY SYNDROME 
Development of opportunistic infections (OIs) due to immunodeficiency, 
and/or tumours in HIV infection defines the status as AIDS. AIDS defining 
OIs and tumours are 
 Protozoal and Helminthic infections 
o Cryptosporidiosis/Isosporiasis 
o Pneumocystis  
o Toxoplasmosis  
 Fungal infections  
o Candidiasis  
o Cryptococcosis  
o Coccidioidomycosis  
o Histoplasmosis  
 Bacterial infections  
o Atypical Mycobacteriosis  
o Mycobacterium tuberculosis  
o Nocardiosis  
o Salmonellosis  
 Viral infections  
o CMV disease  
o Herpes simplex disease 
o Varicella-zoster disease  
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o JC polyomavirus disease 
 Tumours 
o Kaposi’s sarcoma 
o B-cell non-Hodgkin’s lymphoma 
o Primary lymphoma of brain  
o Invasive cancer of cervix /Uterus 
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Correlation of Opportunistic infections with CD4 Lymphocyte 
count (/mm3) 
 
CD4 cell count Infectious conditions 
>500  
 
Candida vaginitis 
200 to 500 Pneumococcal pneumonia 
Pulmonary tuberculosis 
Herpes zoster 
Oropharyngeal candidiasis 
Cryptosporidiosis 
Self-limited Kaposi’s sarcoma 
Oral hairy leukoplakia 
 
<200 Pneumocystis jiroveci pneumonia 
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Disseminated histoplasmosis 
Miliary/extrapulmonary TB 
Progressive multifocal 
leucoencephalopathy 
 
<100 Disseminated herpes simplex 
Toxoplasmosis 
Cryptococcosis 
Cryptosporidiosis 
Microsporidiosis 
Candida oesophagitis 
 
<50 Disseminated cytomegalovirus 
(CMV) 
Mycobacterium avium complex 
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           Opportunistic infection (OI) is a disease caused by microbial 
agent(s) in hosts with defects in humoral and cell mediated immunity. 
Immunocompromised secondary to human immunodeficiency virus (HIV) 
infection, use of immunomodulatory agents (including steroids and 
anticancer drugs) are emerging predisposing factors to OI. Opportunistic 
infections (OIs) may serve as indicators of underlying HIV infection. 
Mortality among HIV-infected individuals is due to improper awareness 
and consequent poor clinical management of opportunistic infections. HIV 
load increases in the presence of ongoing Opportunistic infections, thus 
accelerating progression to clinical acquired immunodeficiency syndrome 
(AIDS). 
         Changes in the CD4 lymphocyte count occur with the institution of 
highly active antiretroviral therapy (HAART) which in turn results in 
changes in OI epidemiology, clinical presentation and treatment outcomes. 
As HAART results in reconstitution of the immune system – certain 
opportunistic infections respond to HAART alone. However, the ensuing 
immune mediated inflammatory response may present as a paradoxical 
worsening of disease. It is, therefore, essential to be able to recognise and 
treat opportunistic infections prior to the institution of antiretroviral agents. 
Opportunistic infections play a role in the clinical staging of HIV infection. 
Opportunistic infections may present as indolent chronic infections 
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(pyrexia of unknown origin), reactivation of latent infections, or as acute 
medical emergencies. They may affect single or multiple organ systems. 
Pathogenesis of GIT Lesions 
[11]
 
It is claimed (but not unanimously accepted) that GIT houses 40% to 65% 
of total immune cells of the body. Immune cells of GIT (all subsets of T-
cells, B-cells and plasma cells, DCs and antigen identifying and processing 
clusters of T-cells and DCs) are organised into Peyer’s patches and 
lymphoid follicles. They are also scattered in the lamina propria and in 
between the lining epithelial cells. Specialised (micro-folded) epithelial 
cells also act as ‘immune cells’; they can take-up and transfer antigens and 
some pathogens to DCs. Epithelial cells bear CD4 receptors and possess 
the capacity to synthesise viral components and cytokines. Histology of gut 
mucosa is similar to that of a tissue harbouring low grade inflammation. It 
reflects ongoing contact and conflict with intestinal flora. 
Mucosal T-memory cells are perpetually in a state of activation. Mucosal 
CD4+ cells are both CCR5+ and CXCR4+. They constitute 80% of the co-
receptor positive population of the total body. For these reasons, the GIT is 
highly susceptible to HIV. 
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Studies on Macaque monkeys and simian immunodeficiency virus (SIV) 
have shown that the kinetics of destruction of immune cells of GIT was 
same as in other parts of the body. 
Depletion of intestinal CD4+ cells was noticeable within days after 
infection. It was same, regardless of route of the infection. It continued 
throughout the course of the infection. By the time SIMD was reached, the 
mucosa, almost totally depleted of immunocompetent cells, was markedly 
thinned out. There was also direct HIV driven mucosal inflammation, a 
lesion called ‘HIV enteropathy’. 
Intestinal disease manifests with episodic diarrhoea, dehydration and 
anorexia. All patients do not exhibit these manifestations. When present, 
they may not be proportionate to the severity of the lesions. Other factors, 
contributory to GIT dysfunction include: fat malabsorption, bacterial 
overgrowth, bile salt excess and reaction to drugs. The patient is markedly 
emaciated. 
 
Pathogenesis of CNS Lesions 
[12]
 
This is the third primary feature of HIV disease, even when HIV cannot 
cross the blood-brain barrier (BBB) and target neurones. Infected 
monocytes carry HIV across the BBB. A pre-existing inflammatory focus 
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in brain attracts HIV infested macrophages and facilitates CNS infection. 
M tropic strain is the main invader. CNS macrophages and microglial cells 
pickup HIV and suffer. About 10% of patients have short meningitic 
episodes at seroconversion. Serious disorder, ‘dementia’ (insidious onset, 
progressive course, impaired memory and concentration, apathy, social 
withdrawal, slow movements, ataxia, etc.) is seen late, when patients are 
approaching SIMD. Incidence (80% to 90%, prior to ART) is now 
declining. Virus and antibodies are present in cerebrospinal fluid (CSF). 
Damage is indirect, probably caused by soluble neurotoxic components 
(gp41 and gp120) of virus and toxic chemicals produced by infected 
microglia. Excess entry of calcium ions into neurones, triggered by toxic 
chemicals, is the postulated mechanism. The lesion is slowly destructive 
(focal glial necrosis) accompanied by reparative gliosis. The brain shows 
cerebral atrophy, widening of sulci and ventricles, microglial nodules, 
perivascular infiltrates and giant cell encephalitis. Clinical severity is out of 
proportion to the magnitude and extent of lesions. The major factor 
responsible for functional loss of brain is invisible: ‘synaptodendritic injury 
(chemical injury that disrupts neuronal network function)’. 
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MANIFESTATIONS OF AIDS OTHER THAN OPPORTUNISTIC 
INFECTIONS: 
CARDIOVASCULAR MANIFESTATIONS 
Prevalence of cardiac involvement in HIV disease varies from 5% to 50% 
but symptomatic involvement occurs in 5% to 7% of patients only. Most 
common clinically significant cardiac abnormality due to direct HIV 
infection is HIV-associated dilated cardiomyopathy. There is evidence of 
myocarditis and HIV has been isolated from myocardial cells. Diagnosis 
can be supported by chest radiograph and electrocardiogram and confirmed 
by echocardiography and elevated serum NTproBNP. CD4+ count in these 
patients is generally >200/cumm. HIV associated cardiomyopathy has poor 
prognosis. Other findings on echocardiography may be diastolic 
dysfunction, pericardial effusion, right ventricular hypertrophy, pulmonary 
arterial hypertension and non-bacterial thrombotic endocarditis. 
GASTROINTESTINAL MANIFESTATIONS 
Manifestations of gastrointestinal tract can be due to HIV itself or drugs 
used in the treatment. Aphthous ulcers are generally found in posterior 
oropharynx and oesophagus. Ulcers produce dysphagia and severe 
odynophagia due to ulcerative oesophagitis. These lesions can be present in 
cases of severe immunodeficiency or during seroconversion. Several 
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studies have demonstrated HIV infected inflammatory cells in the base of 
these lesions suggesting aetiological role of HIV. Endoscopically one or 
multiple ulcers of variable depth with normal intervening mucosa may be 
present, as seen in CMV infection. Short-term steroids or thalidomides are 
effective. Relapse rate of these ulcers is high. Other gastric problems are 
generally rare. 
AIDS ENTEROPATHY 
Direct involvement of intestine by HIV can cause AIDS enteropathy or 
HIV enteropathy. Features include villous blunting, low mitotic figures and 
decrease in villous-crypt ratio. Patients usually present with chronic 
diarrhoea and weight loss. Stool studies, sigmoidoscopy and/or upper 
gastrointestinal endoscopy should be done to rule out other aetiologies. 
Tests of malabsorption are deranged. Treatment includes non-specific 
management like dietary fibre supplementation, antimotility agents, 
octreotide and oral rehydration solution. 
HEPATOBILIARY MANIFESTATIONS 
Direct involvement of liver parenchyma by HIV is not documented, and 
most common cause of hepatic involvement is co-infection with hepatitis 
B, C and administration of antiretroviral therapy. In India hepatitis B co-
infection is present in 2% to 9 % cases and hepatitis C in 2% to 3%. 
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Intravenous drug users may have HCV co-infection in up to 50% to 90%. 
Drugs like nevirapine, protease inhibitors (atazanavir) can cause severe 
acute hepatitis or hepatic failure and their use should be properly 
monitored. 
 AIDS cholangiopathy is a syndrome resembling sclerosing cholangitis 
with papillary stenosis. Diagnosis is made by ERCP and papillotomy can 
relieve obstruction. 
NEUROLOGICAL MANIFESTATIONS 
Neurological diseases due to direct HIV infection occur throughout the 
course of infection and may be due to basic pathology like inflammation, 
demyelination or degeneration. 
AIDS-Dementia Complex (HIV Encephalopathy) 
It is an AIDS defining illness and usually occurs at CD4+ counts 
>200/cumm. If untreated, 15% to 20% of HIV patients will develop this 
entity. AIDS-dementia complex (ADC) or HIV encephalopathy (HIVE) is 
the term used to describe the advanced neurological involvement. HIV 
infects macrophages and glial cells in central nervous system. Release of 
various cytokines/neurotoxins such as interleukin (IL)-1β, tumour necrosis 
factor-α, IL-6 and TGF-β may be responsible for involvement of neuronal 
cells. HIV encephalopathy is a slowly progressive subcortical dementia. 
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Typical complaints are forgetfulness, poor concentration, slowing of 
reasoning, lack of energy drive, mild depression and emotional blunting. 
Patients look apathetic and slow and become socially withdrawn. Sexual 
dysfunction is common. Signs of HIV encephalopathy include impaired 
gait, slowing of rapidly alternating movements, tremor, brisk deep tendon 
reflexes, positive Babinski sign, slowed gaze saccades, sphincter 
impairment including incontinence and frontal release signs. 
Neuropsychological findings such as slowing of psychomotor speed, 
impaired short-term memory and mental flexibility, problem with recalling 
events in correct order, disorientation to time, place and person and finally 
mutism can occur. MRI is preferred imaging modality. It reveals patchy or 
diffuse, hyperintense and relatively symmetrical lesions of white matter 
suggestive of leucoencephalopathy. Cerebrospinal fluid examination 
should be done to exclude alternative diagnosis. A systematic mental status 
examination is an important part of the examination. Quantitative 
neuropsychological tests can be done to see progressive decline in 
neurological functions. Metabolic disorders, depression and anxiety should 
be ruled out. Antiretroviral therapy should be optimised. Highly CNS 
penetrant drugs should best be used from the list of lamivudine, 
zidovudine, nevirapine and indinavir. Outlook for prolonged independent 
life is guarded. 
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HIV Myelopathy 
Myelopathy is present in 20% patients with AIDS. Vacuolar myelopathy is 
pathologically similar to subacute combined degeneration of cord. The 
histological hallmark are vacuoles and lipid laden macrophages most 
prominent is cervical and thoracic spinal cord. It is characterised by 
insidious onset of leg weakness and gait abnormalities. Vague leg 
discomfort and paraesthesias are main sensory symptoms. Bladder and 
bowel dysfunction is also common. Posterior columns of cord can also be 
separately involved producing pure sensory myelopathy and pure sensory 
ataxia. MRI of spinal cord is usually normal. Treatment of myelopathy 
with ART is not much rewarding. 
 
Peripheral Neuropathy 
It can present like acute inflammatory demyelinating polyneuropathy 
resembling GB syndrome. Chronic inflammatory demyelinating 
polyneuropathy (CIDP) with relapsing and remitting course has also been 
documented. Distal sensory neuropathy is most common type of 
neuropathy which can be due to HIV itself or nucleoside analogue drugs. 
Mononeuritis multiplex can also be present. Pregabalin, carbamazepine, 
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gabapentin, tricyclic antidepressant and analgesics can provide 
symptomatic improvement. 
HAEMATOLOGICAL MANIFESTATIONS 
Anaemia is the most common haematological finding. Normocyctic 
normochronic anaemia is found in HIV-associated bone marrow 
suppression. Reticulocyte count is inappropriately low. Drugs like 
zidovudine is the other main culprit. It can block erythroid maturation 
earlier than other components of bone marrow. Mean corpuscular volume 
of RBC is increased. HIV-induced anaemia may respond well to ART 
therapy. Erythropoietin is also effective if its levels are less than that 
expected for severity of anaemia. Zidovudine should be replaced. 
Neutropenia is mostly mild but sometimes it can be severe. The cause of 
neutropenia can be a direct effect or therapy induced. Presence of 
neutropenia generally indicates advanced disease. G-CSF or GM-CSF can 
be of use in increasing counts of neutrophils regardless of the cause. 
Myelosuppressive drugs should be removed. Thrombocytopenia can be due 
to decreased platelet survival probably by immunological mechanism and 
decreased platelet production due to infection of megakaryocytes with 
HIV. 
Treatment should be initiated in patients having platelet count 
<20000/cumm. IVIG and Anti Rh(D) are equally effective but sustained 
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responses are few. Prednisolone 0.5-1.0 mg/kg is used cautiously. 
Splenectomy may be needed in relapsed/refractory cases. 
Persistent generalised lymphadenopathy is an early clinical presentation of 
body response to HIV infection. The condition is defined as lymph node 
enlargement of 2 or more extrainguinal sites of size >1 cm for at least more 
than 3 months without obvious cause. Histologically follicular hyperplasia 
of lymph nodes is present. 
RENAL MANIFESTATIONS 
HIV-associated nephropathy (HIV-AN) is a true direct complication of 
HIV infection occurring in 2% to 10% of HIV infected individuals. 
Clinical presentations of HIV-AN consist of heavy proteinuria (90% have 
nephritic range), rapid deterioration of renal function, normal size of 
kidneys, no or minimal increase in blood pressure. End stage renal disease 
commonly occurs in 6 to 12 months. Kidney biopsy is diagnostic. 
Histology is similar to that of idiopathic focal segmental 
glomerulosclerosis (80%) and mesangial proliferation in 10% to 15% 
cases. HIV-AN also exhibits sclerosis of the whole glomerular tuft which is 
distinctly known as collapsing glomerulopathy. Majority of patients have 
CD4+ T-cell counts <200/cumm. ACE inhibitors and prednisolone with 
tapering dose have been effective in preventing progression of the disease. 
IgA nephropathy can also occur in HIV patients. Acute tubular necrosis 
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can result from nephrotoxic drugs, hypovolaemia, shock and sepsis. Drugs 
like pentamidine, amphotericin, adefovir, tenofovir, NSAIDs and 
radiocontrast agents can cause acute tubular necrosis. Patient should be 
closely monitored and dose adjustments or stoppage of drug should be 
considered once renal dysfunction develops. 
HIV-Associated Wasting 
It is an AIDS defining illness. Center for Disease Control and Prevention 
(CDC) definition of HIV-associated wasting is a weight loss of >10% 
associated with intermittent or constant fever and chronic diarrhoea or 
fatigue lasting >30 days in the absence of a defined cause other than HIV 
infection. Dietary assessment and weight monitoring should be done. Key 
to prevention and management of HIV wasting is aggressive management 
of infection. 
PULMONARY MANIFESTATIONS 
Most of the pulmonary manifestations are due to opportunistic infections 
and should be ruled out before attributing it to HIV disease. Lymphocytic 
interstitial pneumonia, non-specific interstitial pneumonia and increased 
incidence of pulmonary hypertension is seen as the non-opportunistic 
infection manifestations of HIV disease. 
TREATMENT 
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ANTIRETROVIRAL THERAPY 
The advent of antiretroviral drugs in the early 1990s began a revolution in 
the management of HIV infection. Results from various trials 
[13]
 involving 
different drug combinations showing their efficacy opened the 
opportunities to reduce the morbidity and mortality due to HIV/AIDS. The 
combination of atleast three antiretroviral drugs from different groups is 
the current standard of care and is commonly referred to as highly active 
antiretroviral therapy (HAART). There is enough epidemiological and 
clinical evidence that effective combinations of antiretroviral drugs inhibit 
the replication of HIV and reduce viraemia to undetectable levels. 
Treatment slows down the disease progression, improves the quality of life 
and increases the longevity. Success achieved by antiretroviral therapy 
(ART) has now transformed the common perception about HIV infection 
from being a ‘virtual death sentence’ to a ‘chronic manageable illness’. 
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GOALS OF ANTIRETROVIRAL THERAPY 
[14]
 
The primary goals of ART are maximal and durable reduction in plasma 
viral levels and restoration of immunological functions. The reduction in 
viral load also leads to reduced transmissibility. However, as yet there is no 
therapy to eradicate HIV from the body. Antiretroviral (ARV) drugs can 
also be used to reduce the risk of vertical transmission. The ARVs can be 
used after exposure to HIV too, as in cases of accidental needle stick 
injury, and in cases of sexual assault and rape. It is called post-exposure 
prophylaxis (PEP). 
The management of HIV is becoming increasingly complex in view of 
long-term toxicity, drug-to-drug interaction and drug resistance. In 
addition, monitoring facilities such as CD4 counts, viral load estimation 
and drug resistance assay have become necessary for follow-up. 
PRINCIPLES OF ANTIRETROVIRAL THERAPY 
A continuous high level of replication of HIV takes place in the body right 
from the early stages of infection. At least one billion viral particles are 
produced and destroyed each day. The antiretroviral drugs act on various 
stages of replication of HIV in the body and interrupt the process of viral 
replication. Most commonly used drugs target the virus mainly by 
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inhibiting the enzymes reverse transcriptase inhibitors and protease 
inhibitors. Based on the scientific evidence, therapy guidelines have been 
developed by various international agencies such as WHO. They define the 
optimum time, parameters and drugs to initiate and sequence treatment. 
Since, the drug therapy is lifelong, the selection of patients for therapy is 
based on clinical, immunological and viral parameters. Patients 
preparedness for such a prolonged therapy and monitoring ensures their 
adherence. Oppurtunistic infections (OIs), if any, should be treated first. 
Patients should undergo therapy counselling. Along with detailed clinical 
evaluation, co-morbid conditions such as hepatitis B virus (HBV), hepatitis 
C virus (HCV) need to be evaluated for proper selection of ARVs 
considering the efficacy and drug interactions. 
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PREVIOUS STUDIES 
STUDY 1 
[15]
 
         Thinyane et al conducted a prospective observational study, Clinical 
Profiles of HIV-Infected, HAART-Naive Patients Admitted to a 
Tertiary Level Hospital in Maseru, Lesotho, at Queen Elizabeth II (QE 
II) Referral Hospital in Maseru, Lesotho in South Africa a high prevalent 
country for HIV. QEII Hospital is a public sector tertiary level hospital 
which also functions as the national referral hospital. The study population 
included consecutive 105 adult patients (> 15 years) wards between July 
and October 2010. Patients were included if they tested positive for 
HIV(either known to be people living with HIV prior to admission or 
tested positive following admission), not receiving highly active anti-
retroviral therapy (HAART) and admitted for the treatment of HIV-related 
disorders. 
 
The most common symptom was cough which was followed by weight 
loss or wasting and generalised weakness. The commonest opportunistic 
infection was tuberculosis which was followed by oral candidiasis and 
pneumonia. The most common non-infectious HIV-related disease was 
anaemia. 5 patients were diagnosed with symptomatic HIV associated 
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nephropathy and 1 patient with Kaposi Sarcoma .59% were in Stage 3 and 
41.0% were in Stage 4 of HIV infection. More than two thirds of the study 
participants had anaemia. 
 
STUDY 2 
[16]
 
       Nashaba et al did a study on Clinical Profile of HIV/AIDS-infected 
Patients admitted to a New Specialist Unit in Dhaka, Bangladesh - A 
Low-prevalence Country for HIV. This was a retrospective study on HIV 
positive patients admitted in a hospital in Dhaka. The aim of the study was 
to find the common opportunistic infections prevalent in HIV positive 
patients in that population and the status of CD4 count in them. Most of the 
population studied were adults ( >94%). Tuberculosis was the most 
common opportunistic infection which was found in the study population. 
Others common opportunistic infections were oral or oesophageal 
candidiasis , pulmonary infections and herpes zoster. Other common 
clinical manifestations of the disease recorded were weight loss, diarrhoea, 
lymphadenopathy and fever. With respect to CD4 count data, the largest 
number of patients was in the group with CD4 counts from 51to 200 
cells/μL which constituted 31%. The next largest group had CD4 counts of 
above 350 cells/μL which constituted 26%. Although those with a CD4 
count of <50 cells/μL represented 24% of the cohort, 62% of deaths were 
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in this group of patients, indicating high morbidity and  mortality 
associated with low CD4 counts, as reported in various other studies. 
 
STUDY 3 
         Chakaravarthy et al conducted a study on on Clinico-epiemiological 
Profile of HIV Patients in Eastern India 
In this study, 438 HIV positive patients attending the outpatient clinic of 
Sir Sundar Lal Hospital, Institute of Medical science, Banarus Hindu 
University were enrolled. Of these 354 were males (mean CD4 count 179 ± 
9.3 cells/µl) and 84 were females (mean CD4 count 323 ± 28.26 cells/µl). 
The average age of the study subjects during the time of diagnosis was 32.6 
years. The commonest mode of transmission was heterosexual contact in 
80.4% patients followed by blood transfusion in 2.5%. Among the male 
patients, 71.5% were found to be migrant workers. Fever (70.6%), weight 
loss (53.3%), chronic diarrhea (43.9%) and cough (40.3%) were the 
common presenting symptoms. Out of the 438 patients, 66.4% had 
opportunistic infections at the time of reporting to the hospital. The most 
common opportunistic infection was tuberculosis (38.8%) which was 
followed by oropharyngeal candidiasis (20.3%) and diarrhea (12.7%). CD4 
count was inversely proportional to the number of symptoms and 
opportunistic infections. 
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STUDY 4 
[17]
 
                Kaiser et al conducted a study on Clinical Profile of HIV/Aids 
Patients in Srinagar, Kashmir, India. 
The aim of the study was to assess the number of seropositive HIV patients 
enrolled in Government medical college and other associated hospitals in 
Srinagar, Kashmir, India, common signs and symptoms , age and sex 
distribution, modes of transmission and different types of opportunistic 
infections. The mean age of these patients were found to be 34.45±8.40 
with a higher male is to female ratio at 7:1.The summit incidence was 
found in the age group of 30-39yrs of age. Major group of HIV positive 
patients belonged to patients working as security personnel followed by 
migrant labourers and housewives. Sexual transmission was the main mode 
of transmission (90.7 %)followed by homosexual transmission ( 4.7 %). 
78.9 % of patients had fever of greater than 1 month duration, 35.1 % had 
weight loss and 33.5% had diarrhoea. Tuberculosis and 
oral/esophageal/genital candidiasis were the most common opportunistic 
infection followed herpes zoster and varicella zoster. 
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STUDY 5 
[18]
 
         Jayant et al conducted a study on Clinico-epidemiological profile of 
HIV patients attending ART centre in rural Western Maharashtra, 
India, which was a cross-sectional study, conducted at ART centre of a 
rural tertiary care hospital, situated in Maharashtra, India, from the March 
of 2011to September 2011. The study revealed that the most common 
presenting complaints were weight loss, fever, cough, and chronic 
diarrhoea. The  majority of the patients in the study belonged to the 
sexually active age group of 20 to 40 years of age. Heterosexual contact 
was the  commonest mode of acquiring the infection. Tuberculosis (62%) 
was the most common opportunistic infection which was followed by 
pneumosystis carinii pneumonia, herpes zoster, malignancy, candidiasis, 
neurological disorders and ophthalmic manifestations. It was found that as 
the CD4 count decreased, incidence and the number of opportunistic 
infections in patients increased. As per the WHO staging 42.5% patients 
were in stage 3 
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MATERIALS AND METHODS 
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MATERIALS: 
100 randomly selected newly diagnosed HIV infected patients attending 
the ART centre, Tirunelveli Medical College, Tirunelveli. 
DURATION OF THE STUDY: 1 YEAR 
TYPE OF STUDY: DESCRIPTIVE STUDY 
SAMPLE SIZE: 100  
INCLUSION CRITERIA: 
 >15 years of age 
 HIV seropositive 
 Newly registered in ART centre at TVMCH between June 2014 
to may 2015 
 Not on HAART 
EXCLUSION CRITERIA: 
 <15 years of age 
 Already on HAART 
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METHODOLOGY: 
Informed consent was obtained for taking part in this study. Patient 
information, medical history including diagnosis of HIV-infection, 
opportunistic infections and other HIV-related disorders was obtained from 
the patient medical records using predesigned data collection forms. 
Clinical staging of patients was done based on the World Health 
Organisation (WHO) criteria for the Clinical Staging of Established HIV 
Infection. 
Investigations included full blood count, liver function tests, renal function 
tests and CD4 count. 
STATISTICAL ANALYSIS 
Statistical analysis was done using simple percentage analysis. 
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OBSERVATIONS 
AND 
RESULTS 
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SEX DISTRIBUTION 
 
GENDER NUMBER PERCENTAGE 
MALE 63 63 
FEMALE 37 37 
 
In this study the number of males (63%) included in the study was more 
than the females (37%). 
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AGE DISTRIBUTION 
 
AGE RANGE NUMBER PERCENTAGE 
16 – 30 YRS 23 23 
31 – 45 YRS 54 54 
46 – 60 YRS 21 21 
MORE THAN 60 YRS 2 2 
 
More than half of the population in the study were in the age group of 
31 to 45 years of age. 
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SEX AND AGE RELATIONSHIP (MALES – PERCENTAGE) 
 
AGE RANGE NUMBER PERCENTAGE 
16 – 30 YRS 11 17.46 
31 – 45 YRS 35 55.55 
46 – 60 YRS 15 23.80 
MORE THAN 60 YRS 2 3.17 
 
Out of the number of males studied, 55.55% were in the age group of        
31 to 45 years of age. 
 
 
 
MALES 
16 - 30 YRS 
31 - 45 YRS 
46 - 60 YRS 
>60 YRS 
63 
 
SEX AND AGE RELATIONSHIP (FEMALES - PERCENTAGE) 
 
 
AGE RANGE NUMBER PERCENTAGE 
16 – 30 YRS 12 32.43 
31 – 45 YRS 19 51.35 
46 – 60 YRS 6 16.21 
MORE THAN 60 YRS 0 0 
 
More than half of the females were in the age range of 31 to 45 yrs of age. 
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LITERACY – FREQUENCY DISTRIBUTION 
LITERACY MALE FEMALE TOTAL 
LITERATES 53 24 77 
ILLITERATES 10 13 23 
 
 
About 77% of the patients were literates and the rest were illiterates. 
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65 
 
 
 
The percentage of illiteracy was more in the females when compared to the 
males within the study group. 
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BODY MASS INDEX FREQUENCY DISTRIBUTION 
 
BMI – SEX FREQUENCY DISTRIBUTION 
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RANGE MALE FEMALE TOTAL 
NUMBERS % NUMBERS % NUMBERS % 
<16(Severely 
wasted) 
5 7.9% 6 16.2% 11 11% 
<17(Significant 
underweight) 
9 14.3% 12 32.4% 21 21% 
<18.5(Underweight) 16 25.3% 14 37.8% 30 30% 
18.5 to 24.9 
(Normal) 
37 58.7% 16 43.2% 53 53% 
25 to 29.9 
(Overweight) 
6 9.52% 6 16.2% 12 12% 
>30 (Obese) 4 6.34% 1 2.7% 5 5% 
 
After applying the WHO BMI classification 30% of the study group were 
found to be underweight, 21% were significantly underweight and 11% 
were severely wasted. 
37.8% of females were found to be underweight compared to 25.3% of 
males. 
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CLINICAL STAGE FREQUENCY DISTRIBUTION 
CLINICAL 
STAGE 
MALE FEMALE TOTAL 
STAGE 1 25 16 41 
STAGE 2 7 6 13 
STAGE 3 29 14 43 
STAGE 4 2 1 3 
 
 
41% of the study group population were asymptomatic (Stage 1). 43% of 
them were in the clinical stage 3. Only 3% were in the clinical stage 4. 
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The distribution of clinical stage among males and females in the study 
population showed relatively similar trend. 
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HIV ASSOCIATED IMMUNODEFICIECY BASED ON CD4 
COUNT 
(Based on WHO immunological classification for established HIV 
infection) 
IMMUNODEFICIENCY CD4 
VALUE 
MALE FEMALE TOTAL 
NOT SIGNIFICANT >500 12 10 22 
MILD 350 - 499 10 8 18 
ADVANCED 200 - 349 19 8 27 
SEVERE <200 22 11 33 
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Although only three percentage of the study population fall into clinical 
stage 4, based on CD4 counts 33 percentage of study population are having 
severe immunodeficiency.  
19.04% 
15.87% 
30.15% 
34.74% 
0.00% 
5.00% 
10.00% 
15.00% 
20.00% 
25.00% 
30.00% 
35.00% 
40.00% 
NOT 
SIGNIFICANT 
MILD ADVANCED SEVERE 
IMMUNODEFICIENCY BASED ON CD4 -
MALES 
IMMUNODEFICIENCY 
27.02% 
21.62% 21.62% 
29.72% 
0.00% 
5.00% 
10.00% 
15.00% 
20.00% 
25.00% 
30.00% 
35.00% 
NOT 
SIGNIFICANT 
MILD ADVANCED SEVERE 
IMMUNODEFICIENCY BASED ON CD4 - 
FEMALES 
IMMUNODEFICIENCY 
72 
 
 
 
DISTRIBUTION OF IMMUNODEFICIENCY AMONG VARIOUS 
CLINICAL STAGES 
 
Majority of the patients in clinical stage 1 had either mild or non 
significant immunodeficiency. 12.2% of the patients, though in clinical 
stage 1 (asymptomatic) had severe immunodeficiency. 
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Moving from clinical stage 1 to clinical stage 4 there is an increase in 
patients in the advanced and severe immunodeficiency stage. The patients 
who had clinical stage 4 were all having severe immunodeficiency, 
suggesting a positive correlation between immunodeficiency based on CD4 
count and clinical staging. 
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DISRTIBUTION OF ANEMIA BASED ON HEMOGLOBIN 
VALUES 
RANGE MALE FEMALE TOTAL 
NORMAL 27 14 41 
MILD ANEMIA 25 4 29 
MODERATE 8 16 24 
SEVERE 3 3 6 
 
 
The prevalence of moderate to severe anaemia in study group was more in 
females compared to males. 51.35% of female patients had moderate to 
severe anaemia compared to 17.46 % of male patients. 
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DISTRIBUTION OF WBC COUNT 
 
16% of the study population had leucocytosis and 3% had leucopenia. 
DISTRIBUTION OF PLATELET COUNT 
 
7% of the study population had thrombocytopenia. 
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DISTRIBUTION OF SERUM CREATININE LEVELS 
 
Serum creatinine was found to be elevated above normal limit in 6% of 
patients. 
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DISTRIBUTION OF SERUM BILIRUBIN LEVELS 
 
Serum bilirubin was found to be above the normal range in 2% of the 
patients. 
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DISTRIBUTION OF SERUM TRANSAMINASES LEVELS (SGOT 
AND SGPT)  
 
SGOT was found to be elevated in 23% of patients and it was above two 
times the upper limit of normal in 7% of patients. 
SGPT was found to be elevated in 24% of patients. It was above two times 
upper limit of normal in 3% of patients. 
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SYMPTOMATOLOGY  
 
SYMPTOMS MALE FEMALE TOTAL 
WEIGHT LOSS 8 6 14 
LOSS OF APPETITE 8 4 12 
DYSPHAGIA 10 5 15 
DIARRHOEA 8 7 15 
FEVER 16 12 28 
COUGH 17 7 24 
ABDOMINAL PAIN 2 1 3 
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SYMPTOMATOLOGY – MALES 
 
 
SYMPTOMATOLOGY – FEMALES 
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The most common symptom of the patients in the study population is fever 
(28%), followed by cough (24%), dysphagia (15%), diarrhoea (15%), eight 
loss (14%), loss of appetite (12%) and abdominal pain (3%). 
Cough (26.98%) was the predominant symptom among male patients, but 
the predominant symptom in the females was found to be Fever (32.43%).  
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OPPORTUNISTIC INFECTIONS – FREQUENCY DISTRIBUTION  
 
OPPORTUNISTIC 
INFECTIONS 
MALE FEMALE TOTAL 
TUBERCULOSIS 26 10 36 
ORAL 
CANDIDIASIS 
12 5 17 
DIARRHOEAL 
DISEASE 
8 7 15 
HERPES ZOSTER 1 0 1 
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OPPORTUNISTIC INFECTIONS IN MALES FREQUENCY 
DISTRIBUTION 
 
OPPORTUNISTIC INFECTION IN FEMALES – FREQUENCY 
DISTRIBUTION 
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The commonest opportunistic infection related to HIV infection found in 
the study was Tuberculosis which was found in 36% of the study 
population. It was followed by Oral Candidiasis in 17% of patients and 
Diarrhoeal disease in 15% of the patients. 
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             DISCUSSION 
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           HIV/AIDS as already discussed has several clinical stages, variable 
pathogenesis and opportunistic infections. In this study, the clinical and 
laboratory profile of 100 patients, who were newly diagnosed were studied 
and documented. There were 63 male patients and 37 female patients in the 
study population. The majority of the newly diagnosed HIV patients 
belonged to the age group of 31 to 45 years, suggesting that the incidence 
and prevalence of the disease is more common in the sexually active period 
of life. 77% of the study population were literates and the rest were 
illiterates. 
        Body mass index distribution showed that 30% of the study 
population were under weight. Among them 21% were significantly 
underweight and 11% were severely wasted. These individuals may be part 
of HIV wasting syndrome. 37.8% of females were underweight compared 
to 25.3% of males. 
        WHO clinical staging and immunological classification were applied 
to the study population. 41% of the patients were in the clinical stage 1 and 
43% in clinical stage 3. Higher number of patients in clinical stage 3 is 
because of the higher prevalence of Pulmonary Tuberculosis co-infection. 
Another factor is that in Tirunelveli medical college all patients diagnosed 
with tuberculosis are screened for HIV and, if they tested positive they fell 
into the category of clinical stage 3. It also illustrates the importance of 
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screening for HIV in patients with Tuberculosis and the vice versa. The 
clinical stage distribution showed a relatively similar trend in both males 
and females. 
        33% of the study population had severe immunodeficiency (based on 
WHO immunological classification for established HIV infection). 60% of 
the population had advanced immunodeficiency or more. When this 
immunological classification was applied to patients in individual clinical 
stage, there was a increase in patients with advanced or severe 
immunodeficiency when moving from clinical stage 1 to clinical stage 4 as 
expected. All the three patients who were in clinical stage 4 were found to 
be having severe immunodeficiency. Though various studies suggest that 
CD4 alone cannot be a true indicator of the immunodeficiency in a HIV 
infected patient, in this study there is a positive correlation between the 
immunodeficiency classification based on CD4 count and clinical stage of 
the disease. 
             The prevalence of moderate to severe anaemia in the study 
population was 30%. 51.35% of females had moderate to severe anaemia 
compared to 17.46% in males. Hence there is increased prevalence of 
anemia in the female HIV infected patients, when compared to males. This 
may be explained by the fact that anemia is more prevalent in females than 
in males in this locality. 
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        16% of the study population had leucocytosis and 3% had 
leucopenia.7% of the study population had thrombocytopenia. It is also 
important to note that unexplained anaemia (<8 g/dl), neutropenia (<0.5 × 
109 per litre) or chronic thrombocytopenia (<50 × 109 per litre), in a HIV 
infected patient is classified as clinical stage 3 according to WHO. So the 
cause of such haematological problems in a HIV infected patient should be 
investigated. 
     Serum creatinine was found to be elevated in 6% of patients. The 
presence of increased serum creatinine in a HIV positive patient may be 
due to either HIV itself (HIV associated nephropathy) or may be due to 
antiretroviral drugs. This study was conducted in HAART naïve patients, 
so there is no possibility of anti retroviral drugs induced renal failure in this 
study group. Also HIV infected individuals are more prone to prerenal 
azotemia due to volume depletion occurring from salt wasting, poor 
nutrition, nausea and vomiting. To find out the presence of HIV associated 
nephropathy additional investigations should be done like 24 hours urine 
protein to demonstrate nephrotic range of proteinuria and renal biopsy to 
prove the presence of focal segmental glomerulosclerosis. 
    Serum bilirubin was found to be elevated in 2% of the patients. Liver 
transaminase enzymes were elevated in 24% of patients. However SGOT 
and SGPT was elevated two times upper limit of normal only in 7% and 
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3% respectively. Such abnormality in HIV infected patients prompts the 
screening for hepatitis B or C co-infection in them. Many of the patients in 
this study who were found to be HIV infected were already taking anti 
tuberculous therapy for Tuberculosis. Elevated serum bilirubin and 
transaminase levels above 2 times upper limit of normal in such patients 
may be due to drug induced liver injury. Those with only transaminase 
elevation less than 2 times the upper limit of normal may be due to liver 
adaptation to anti tuberculous therapy. 
      The most common symptom in the study population was fever (28%), 
followed by cough(24%). Cough was the most common symptom in male 
patients, while in females fever was the most common symptom. Patel AK 
et al and Kothari K et al in their respective studies had already found fever 
as the commonest symptom. This proved to be true in this study also. 
    The commonest opportunistic infection in study population was 
pulmonary tuberculosis in 36% of the patients. It was followed by oral 
candidiasis (17%) and diarrhoeal disease (15%). According to Patel AK et 
al, the most common opportunistic infection was oral candidiasis followed 
by tuberculosis. Studies conducted by Vajpayee et al and Zaheer et al had 
shown that tuberculosis is the commonest opportunistic infection. 
Tuberculosis as the most common opportunistic infection in this study can 
be attributed to the high prevalence of tuberculosis in this locality. 
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CONCLUSION 
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                Most of the newly diagnosed HIV infected patients belong to the 
age group of 31 to 45 years of age. There is a positive correlation between 
the clinical stage and the immunodeficiency based on CD4 count. Fever is 
the most common symptom in newly diagnosed HIV infected patients, 
followed by cough. Tuberculosis is the most common opportunistic 
infection followed by oral candidiasis. All patients with HIV infection 
should be screened for Tuberculosis and vice versa.   
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ANNEXURE 1 
WHO CLINICAL STAGING FOR HIV IN ADULTS 
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ANNEXURE 2 
WHO IMMUNOLOGICAL CLASSIFICATION FOR 
ESTABLISHED HIV INFECTION 
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ANNEXURE 3 
PROFORMA 
 
Patient Name:       Age    
Address        ART No 
                                                                                         Height: 
                                                                                         Weight: 
 
Symptoms: 
 
 
 
 
Clinical Findings 
 
 
 
 
Comorbidities  
 
 
CD4 Count: 
 
CLINICAL STAGE: 
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Sodium : 
Potassium: 
 
Liver Function Test : 
 
 
 
  
Hb   
TC   
DC   
ESR   
Platelets   
RBS Urea/ 
Creatinine 
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ANNEXURE 4 - MASTER CHART 
 
patient name age sex ART no literacy BMI Clinical stage CD4 TC HB% platelet SGOT SGPT bilirubin creatinine urea
muppidathi 46 male 6752 yes 25.8 3 131 4600 11.1 4.77 35 44 0.8 1 37
sivasangu 64 male 6754 no 18.81 2 336 8100 12.6 1.83 24 15 0.6 1.3 32
madasamy 43 male 6756 yes 24.31 1 448 9000 16.8 4.83 17 45 0.8 0.8 30
thennarasu 30 male 6757 yes 22.65 1 475 11,700 14.7 3.77 18 53 0.8 0.8 20
velsamy 30 male 6759 yes 16.52 1 420 5800 12 4.21 40 39 0.9 0.9 32
indira 45 female 6760 no 15.86 3 37 2000 6.7 1.99 18 23 0.7 0.7 16
masanam 33 male 6761 yes 18.36 1 206 8000 15 2.55 20 45 0.7 0.7 18
kasiham 37 female 6765 no 25.07 1 480 6100 12.1 3.01 15 21 0.6 0.7 28
meena 16 female 6766 no 20 1 233 8400 12.1 2.33 47 39 0.6 0.6 19
baskar 32 male 6768 yes 18.59 3 256 6700 14.6 3.79 26 43 0.5 0.7 19
ganesan 35 male 6770 yes 19.53 3 31 12200 7.9 1.7 26 35 4.2 0.7 30
kaliammal 40 female 6772 no 14.8 3 393 8000 10.9 3.83 30 42 0.6 1.4 64
pandiyaraj 38 male 7004 yes 18.72 3 252 2500 12.3 2.23 92 79 0.6 0.8 18
sundarraj 39 male 7005 yes 22.22 2 28 4300 12.3 2.7 37 42 0.6 1 25
joeswa 40 male 7006 yes 13.76 3 32 6300 8.9 4.88 28 20 0.7 0.8 18
athina 25 female 7007 yes 30.61 1 182 6000 12.8 4.13 18 16 0.4 0.8 18
gopal 38 male 7008 no 19.07 3 253 9500 8.4 2.98 16 12 0.5 0.9 20
gomathy 33 female 7009 no 16.84 3 384 5800 11.8 1.82 28 26 0.8 0.9 30
sudalaimani 23 male 7010 yes 24.31 1 713 6200 12.3 1.91 28 26 0.6 1 24
velkumar mariappan 32 male 7012 yes 22.14 1 361 8800 12.4 4.01 20 20 0.8 1.2 19
sathiya rani 27 female 7013 yes 20.82 1 679 7000 13 4.21 22 15 0.9 0.9 16
ananda kumar 37 male 7019 yes 23.5 1 283 9900 15.9 5.01 30 36 0.5 1 16
palani 41 male 7021 yes 18.26 2 287 6900 11.1 3.86 23 20 0.6 0.7 19
sudalee 39 female 7023 yes 19.7 2 437 5600 13.7 3.34 15 13 0.5 1 16
mangalaraj 57 male 7024 yes 19.72 3 60 7500 10.4 3.21 45 52 1.4 1 30
manimaran 21 male 7042 yes 18.73 1 631 12,800 15.6 4.88 23 29 0.5 0.9 18
ananth 20 male 7043 yes 15.35 1 81 6800 11 4.11 18 20 0.4 0.8 16
abdul hameedu 60 male 7044 no 20.96 4 50 4700 14.2 5.34 25 16 0.8 1 16
manikandan 30 male 7046 yes 20.93 3 479 1900 13.8 3.12 38 29 0.8 0.8 18
samy 41 male 7045 yes 21.3 2 33 5500 11.3 2.13 22 25 0.6 0.8 30
mallika 29 female 7047 yes 22.63 2 662 8000 12.3 4.49 37 25 0.8 0.7 19
anandh 40 male 7048 yes 21.08 3 596 8800 11 1.83 24 27 0.4 0.6 30
paramasivan 46 male 7049 no 22.31 3 239 5700 14.4 5.08 16 14 0.7 0.8 18
mohamed ajesh 44 male 7145 yes 18.73 2 802 4700 11.7 1.2 25 18 1 1 20
rosammal 40 female 7146 yes 22.67 3 172 4100 11.3 1.78 28 23 0.5 0.9 16
shanmugavel 48 male 7147 no 17.12 3 56 4900 12.9 2.21 57 39 0.6 1 18
murugan 52 male 7150 yes 15.56 3 206 5600 10.1 3.44 32 11 0.7 0.8 16
poomari 28 female 7051 yes 16.2 2 420 11,700 8.9 1.4 129 80 0.7 0.8 30
rajesh 37 male 7052 yes 24.21 1 404 6200 15.1 1.4 54 50 1.5 0.8 17
nainar murugan 33 male 7053 yes 20.68 1 272 5700 13.6 2.1 43 40 0.5 1 16
navaneethakrishnan 24 male 7054 yes 20.45 1 122 6300 11 1.85 32 22 0.8 0.8 24
anthony 54 male 7055 no 20.2 3 146 6200 11.6 2.33 25 15 0.6 1 18
manikandan 20 male 7056 yes 15.27 2 1198 8000 10.5 2.18 32 34 0.8 0.9 16
shanmugapriya 18 female 7057 yes 19.56 1 842 7200 8.5 1.2 43 51 0.9 0.8 20
manonmani 47 female 7058 no 16.87 3 221 4300 6.1 1.5 109 100 0.9 0.8 19
sundar nadar 50 male 7059 yes 21.5 3 156 8000 10.9 1.81 27 16 0.8 0.8 20
mydeen meeral 45 female 7060 no 16.01 4 93 6300 12.4 1.75 130 50 1 1 22
nadarajan 50 male 7263 yes 26.03 1 207 5000 12.9 2.95 27 23 0.6 1 23
madathi 55 female 7264 no 26.16 2 404 5700 11.9 3.15 20 25 0.6 1 37
mariammal 36 female 7265 yes 15.3 3 35 7500 8.5 3.57 150 172 0.4 0.7 23
velukonar 60 male 7266 yes 18.75 3 526 8600 11.6 3.66 35 12 0.4 1.2 27
arumugam 35 male 7267 yes 19.53 1 259 9800 9.6 3.13 26 32 0.4 1 21
sakthi 34 male 7268 yes 19.53 4 98 6600 13.1 3.75 62 80 1.2 0.8 39
selvi 35 female 7270 yes 15.97 3 53 7000 10.8 2.78 59 70 0.6 0.8 20
kumar 33 male 7271 yes 16 3 295 7200 14 1.84 32 34 0.9 0.8 32
muthukumar 29 male 7273 yes 18.8 1 600 5900 13.7 1.64 172 88 0.8 0.6 16
regina 45 female 7274 no 16.88 3 250 3900 7.9 1.82 17 11 0.4 0.7 18
ganesan 41 male 7275 yes 21.67 1 267 8300 12.5 2.8 40 38 0.6 0.9 20
iyappan 56 male 7276 yes 16.16 3 114 4400 7.5 2.95 31 23 0.5 0.8 16
kanimozhi 26 female 7277 yes 20.93 1 330 3500 10.4 2.06 103 76 0.4 0.7 19
rajeshwaran 55 male 7278 yes 21.33 3 33 10,400 8.9 4.47 38 54 0.4 0.6 19
saravanan 43 male 7279 yes 17.25 1 321 9500 9.3 3.45 32 23 0.4 0.9 28
muthumari 39 female 7280 yes 14.2 3 131 6000 9.9 3.6 48 35 0.4 0.6 16
shanthi 40 female 7281 yes 21.33 1 588 8200 15 2.3 40 38 0.8 0.1 40
sudha 40 female 7282 yes 17.36 3 122 7900 9 3 18 34 0.4 0.6 18
saroja 30 female 7283 no 18.33 2 992 6500 13.4 3.2 18 18 0.4 0.7 26
suganya 27 female 7284 yes 21.4 1 626 6200 12.5 3.11 20 27 0.6 0.6 17
paul durai 40 male 7285 no 25.8 2 501 7200 14 2.38 42 46 0.5 1 18
mathakani 55 female 7286 yes 14.76 3 201 10,300 8 2.29 34 44 0.4 0.7 16
mariappan 40 male 7287 yes 26.91 1 237 8600 14.4 2.89 48 17 0.6 0.7 16
sekar 46 male 7288 yes 18.02 3 295 6300 17.1 1.85 22 20 0.7 0.7 22
senthil 25 male 7289 yes 30.86 1 665 9100 15 1.91 27 10 1 0.7 23
helen 35 female 7290 yes 23.23 2 39 4800 13.1 2.1 46 28 0.6 0.7 22
manickam 28 male 7292 yes 23.44 3 305 4800 11.9 3.2 33 53 0.5 0.9 16
murugan 60 male 7293 yes 20.31 3 167 12000 14 1.25 40 36 0.8 1.1 40
rajagopal 40 male 7300 yes 17.09 3 42 6300 11.1 4.82 181 84 0.4 0.7 16
karupayee 54 female 7299 no 24.77 1 1141 11600 11.7 2.53 41 26 0.4 1.6 48
esakimuthu 45 male 7298 yes 16.59 3 67 6500 11.4 1.69 30 39 0.6 0.9 20
parvathy 37 female 7297 yes 25.45 1 866 5800 13 1.82 40 36 0.8 0.9 31
manoharan 38 male 7296 yes 28.57 1 240 6200 14.5 2.69 32 24 0.7 0.9 16
bindhu 26 female 7295 yes 19.53 1 368 5800 14 2.12 45 36 0.7 0.9 32
revathi 29 female 7294 yes 27.33 1 647 10100 10 2.14 21 12 0.5 0.6 18
ponraj 40 male 7339 yes 31.25 1 535 8100 16 2.62 37 22 0.7 0.8 20
arumugam 31 male 7342 yes 16 3 282 10300 13 2.57 23 13 0.4 0.8 16
murugan 50 male 7340 yes 25.29 1 351 6100 15.3 2.9 18 21 0.8 1 30
chelladurai 35 male 7357 yes 20.4 3 192 10100 13 2.87 17 16 0.6 0.7 31
jeyaraman 50 male 7336 yes 21.64 3 48 5300 11.9 2.18 30 26 0.4 0.6 15
rajesh 18 male 7348 yes 18.08 1 196 6600 15 1.98 38 30 1 1.3 23
surya rani 49 female 7338 yes 18.51 3 303 5500 10.9 2.1 40 15 0.4 0.7 18
sudalaimuthu 65 male 7350 no 23.87 3 470 5300 11.2 1.98 20 12 0.4 1.1 24
sudalaimuthu 36 male 7349 no 20.44 1 358 7500 14.6 3.33 30 12 0.7 0.8 16
mary 48 female 7347 yes 22.71 1 176 8900 9.2 3.47 31 25 0.3 0.9 15
anand 42 male 7346 yes 31.24 1 785 7500 12.5 3.04 24 19 0.6 0.7 16
mani rose mary 33 female 7345 yes 22.34 3 144 6900 10.3 3.03 39 14 0.4 0.7 18
nagarajan 50 male 7344 no 30.67 3 539 7344 16.6 1.67 41 17 0.9 0.8 19
roja 27 female 7343 yes 26.82 1 200 9500 13.2 3.7 30 15 0.8 0.8 16
vadivu 41 female 7341 yes 28.98 3 158 4000 11.8 2.51 18 10 0.4 0.6 16
raju 38 male 7355 yes 19.9 1 456 6700 12 3.33 28 29 0.6 0.7 18
esakimuthu 41 female 7356 no 16.67 1 550 9800 13 2.01 40 44 0.8 0.8 16
mariammal 44 female 7262 no 20.7 1 436 5500 10.3 3.05 28 30 0.7 1 36
